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ABSTRACT
Vibrio gazogenes, a Gram-negative species of marine bacteria, was capable of
transporting

20

nm

(diameter)

surface-carboxylated,

polystyrene,

fluorescent

FluoSpheres® microspheres (excitation/emission = 505/515) through the outer membrane,
which was indicated by a detectable decrease in the fluorescence intensity of the
nanoparticles in the culture medium. A mechanism of transport was investigated involving
the ATP-binding cassette (ABC) protein transporters that traverse the outer membrane.
Inhibition of the ABC transporters did not prevent the entry of the nanoparticles into the
cell, suggesting there was an alternate mechanism of transport.

The addition of

nanoparticles to the culture medium also did not provide any growth benefits for Vibrio
gazogenes.
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CHAPTER 1
INTRODUCTION

Nanomedicine
Nanotechnology is a rapidly developing field with diverse applications and has emerged
as a hot topic in the scientific community. Emphasis within this field is placed on
engineering and utilizing nanoscale materials to function in more-efficient and -effective
capacities than macroscale materials.

One discipline exploring the possibilities and

potential of nanotechnology is nanomedicine.

Nanomedicine combines traditional

therapeutic concepts with current nanotechnological advancements to create novel
approaches for the screening, diagnosis, and treatment of infections and diseases. The
novelty of nanomedicine lies in the unique ability to modify the physicochemical properties
of the nanomaterials (nanoparticles). Nanoparticles have traditionally been defined as
being 1 to 100 nm in size in at least one dimension (ASTM 2006); however, newer
definitions are inclusive of materials up to 1,000 nm in size (Wagner et al 2006). Complex
engineering can impart specific optical, magnetic, electronic, and biological properties to
the nanoparticles, as well as, certain shapes, sizes, surface chemistries, and chemical
compositions (Kim et al 2010) (Figure 1.1).

Modifiable characteristics allow the

nanoparticles to be finely tuned to target specific components of biological systems at the
atomic and molecular level. It is believed that nanoparticle-based therapies will have a
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significant impact on healthcare in the future by providing effective diagnostics and
treatments that will improve the quality of life, extend life expectancies, and ultimately
lower the overall cost of healthcare worldwide (Pautler and Brenner 2010). One area where
the innovation provided by nanomedicine is desperately needed is in the treatment of
antibiotic-resistant bacterial infections, which are responsible for the largest number of
deaths worldwide for adults under the age of 60 (Fauci et al 2005).

Re F, Moresco R, Masserini M. 2012. Nanoparticles for neuroimaging. J Phys D: Appl Phys
45(7): 073001 (12 pp). ©IOP Publishing. Reproduced with permission. All rights reserved.

Figure 1.1 Different types of Nanoparticles

Creation of Superbugs
An estimated 4 to 5 billion dollars is spent yearly treating infections caused by
antibiotic-resistant bacteria (Fauci et al 2005). These ‘superbugs’ have developed highly
evolved resistance mechanisms over time in response to their overexposure to large
2

quantities of natural and synthetic antibiotics. The two major factors attributed to the
creation of superbugs are antibiotic overuse and misuse. According to the CDC, three
billion prescriptions for antibiotics are written annually by clinicians to treat infections,
and at least fifty percent of these are incorrectly prescribed (CDC 2010). In addition, many
patients are non-compliant when being treated with antibiotics and may even use
previously prescribed antibiotics to treat subsequent illnesses (Reed et al 2002). In
developing countries, lack of regulation allows people to purchase antibiotics to treat selfdiagnosed illnesses (Vento and Cainelli 2010). Another major issue is the feeding of
massive quantities of antibiotics to livestock by animal husbandry companies in order to
promote growth, exposing consumers to antibiotics on a regular basis (Singer et al 2003).
Due to these factors, antibiotic-resistant bacteria traditionally seen in clinical settings are
now migrating into the global community, creating a major public health crisis (Cars et al
2011).
Biofilm Formation
Many multi-drug resistant bacterial strains are difficult to treat due to their ability to
form biofilms, which confer strong antibiotic resistance properties to the community of
bacterial cells within the biofilm. The formation of the biofilm state occurs after exposure
to environmental stressors that trigger a series of physiological changes facilitating
bacterial growth and survival in hostile environments (Costerton et al 1995) (Figure 1.2).
Once the bacteria transition to the biofilm state, they become 10-1,000 times more resistant
to the effects of antimicrobials (Morton et al 1998).
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Figure 1.2 Biofilm Formation
Antibiotic Resistance in Biofilm
Increased antibiotic resistance in the biofilm state is mainly the result of the following
factors: restricted antimicrobial penetration, spatial and population heterogeneity, quorumsensing systems, enhanced exchange of resistance genes, and multi-drug efflux pumps.
Restricted antimicrobial penetration is an effect generated by the formation of an
exopolysaccharide matrix and reduced fluid flow (diffusion limitation) within the biofilms
(Morton et al 1998). The exopolysaccharide matrix either prevents or significantly reduces
the entry of antimicrobials into the biofilms, while diffusion limitation lowers their rate of
transport through the biofilms (Costerton et al 1995). Spatial and population heterogeneity
describe the variation in concentrations of metabolic substrates and by-products as well as
differences in metabolic activity among the bacteria (Morton et al 1998). Bacterial cells in
slow growing or inactive states (persisters) are able to resist treatment because antibiotics
tend to target actively growing cells (Singh et al 2009). Persisters can become active after
treatment, leading to reinfection, long-term colonization, and persistent infections.
4

Quorum-sensing systems allow the bacteria to communicate with each other through
chemical signaling once a certain cell concentration is reached during biofilm formation
(Nadell et al 2008). After the quorum has been achieved, the bacteria are able to coordinate
their activities and alter their gene expression in response to any perceived threats, making
them less susceptible to antimicrobials. The enhanced exchange of resistance genes
amongst bacteria within the biofilm helps to provide antibiotic resistance to the biofilm as
a whole. Multi-drug efflux pumps facilitate the export of antibiotics from the interior of
the biofilm cells (McKeegan et al 2002). The combination of these resistance factors
within the biofilm have rendered several potent antibiotics useless thereby creating the
need for the development of new treatment methods that will increase the efficacy of
currently available antibiotics by allowing them to travel efficiently through the biofilm
and overcome the resistance mechanisms.
Antibiotic Discovery and Development
A significant issue in combating the problem of antibiotic-resistance is the lack of
progress in antibiotic discovery and development. The majority of antibiotics in use today
were discovered during the “golden age,” which spanned from the 1940s to the 1960s
(Fabbretti et al 2011). Since this period, one antibiotic (doripenem) has been introduced
and only three new compounds are in advanced clinical development (Boucher et al 2009).
Even more discouraging is the fact that only 5 of the largest pharmaceutical companies
currently have active antibiotic discovery programs (Boucher et al 2009).

Smaller

biotechnology companies capable of doing the research are unable to continue funding the
development projects because they rely heavily on unstable venture capital to support their
work (Fabbretti et al 2011). FDA approval of new antibiotics was also reduced by 75%
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from 1983 to 2007, and the numbers continue to decline (Boucher et al 2009). This
innovation gap led the Infectious Diseases Society of America to propose the 10 x ’20
Initiative in 2009, which asked U.S. and European Union companies to develop ten new
antibiotics within the next 10 years (IDSA 2010).
Nanomedicinal Therapies
The development of nanomedicinal therapies to assist in the fight against antibioticresistant strains is rapidly gaining momentum. Many papers have shown the ability of
silver and gold nanoparticles as well as liposomes to treat drug-resistant bacteria (Couvreur
et al 1991; Lara et al 2010; Ray et al 2013). Nanoparticles are capable of binding to
bacterial membrane receptors and overcoming resistance mechanisms in planktonic cells
and biofilms, making them exceptional carriers for drug delivery (Kumar et al 201; Bae et
al 2011; Feng et al 2000; Rai et al 2009; Taylor and Webster 2009; Raghupathi et al 2011).
The unique ability of nanoparticles to be physically- and chemically-modified gives
researchers the ability to design nanoparticles with functional groups attached to the
surface that act as ligands capable of bonding thousands of antibiotic molecules, effectively
concentrating the dosage (Taylor and Webster 2011; Wang 2015). The delivery of massive
doses of antibiotics to the cell surface could potentially saturate the multi-drug efflux
pumps and other counter-mechanisms, rendering them useless (Wang 2014). The large
surface-to-volume ratio conferred by the small size of the nanoparticles allows them to be
highly diffusive, and therefore, capable of infiltrating biofilms and reaching previously
inaccessible targets (Pinto-Alphandary et al 2000). Nanoparticles also behave as catalysts
by driving chemical reactions at an elevated rate, which could result in antibioticnanoparticle conjugates that are adept at treating planktonic cells or biofilms at a faster
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rate, consequently reducing treatment times. While nanomedicinal therapies seem very
promising and a favorable alternative to traditional therapies, there is much that is unknown
about how the nanoparticles interact with the bacterial cells, especially within bacterial
biofilms (Fabrega et al 2009; 2011; Nevius et al 2012). For example, it is unknown whether
all bacteria are capable of nanoparticle transport into cells or if the transport mechanisms
vary depending on the species. In order to initiate the development of potentially lifesaving and ground-breaking therapies, a thorough understanding of nanoparticle uptake
and transport mechanisms must be acquired, with the aim of designing methodologies for
the effectual delivery of nanoparticles to their intended destinations.
Elucidation of Nanoparticle Transport Systems
For many years, it was believed that particle uptake was solely a eukaryotic process, so
the elucidation of nanoparticle transport systems is a relatively new area of study. Of the
studies showing the ability of bacteria to transport various types of nanoparticles with
diameters less than 80 nm, only a few have actually proposed a transport mechanism
(Kumar et al 2011; Stojak et al 2011; Xu et al 2004; Murat et al 2010; Reith et al 2006;
Kloepfer et al 2005; Lonhienne et al 2010). These studies also specifically focused on
studying the interactions between Gram-negative bacteria and nanoparticles because of the
difficulty in treating resistant, Gram-negative bacteria, which is due to the possession of a
hydrophobic outer membrane that acts as a barrier against many bactericidal agents and the
large number of multi-drug efflux pumps located within their plasma membranes (Morton
et al 1998). The information known about basic molecular transport in Gram-negative
bacteria is that it generally occurs either through passive or active transport systems;
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therefore it is important to determine which of these systems play a role in nanoparticle
transport.
Passive transport
Passive transport is a diffusive process; therefore, molecules travel across the semipermeable plasma membranes by moving down their concentration gradient. This requires
no ATP energy from the cell. In some cases, the cell requires a carrier protein to escort the
molecules through the plasma membranes (facilitated diffusion) because they are either too
large for simple diffusion or not water-soluble. Even though the carrier protein assists in
the diffusive process, it still requires no energy input from the cell. Passive diffusion in
Gram-negative bacteria, whether simple or facilitated, requires molecules be able to fit
through porins located in the outer membrane. Porins are wide, water-filled channels with
diameters varying between 0.6-2.3 nm that act as molecular sieves by exhibiting selectivity
for molecules of certain sizes and molecular charge (Hancock and Bell 1988; Benz et al
1985). Due to the size-exclusion limits of the porins, it is widely accepted that nanoparticle
transport occurs through an active transport system in Gram-negative bacteria (Stojak et al
2011; Mohammed et al 2011).
Active Transport
Active transport requires ATP as an energy source and is the movement of molecules
across the semi-permeable plasma membranes against their concentration gradient. Large
objects needing to travel over long distances in the cell also require active transport
mechanisms to assist in their movement (Mignot and Shaevitz 2008). At the cell surface,
active transport involves the use of carrier proteins powered by the generation of ATP
energy to pump the molecules into the cell. A major class of active transport proteins that
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are found in highly-conserved numbers in Gram-negative bacteria are ATP-binding
cassette (ABC) transporters, which are integral transmembrane proteins responsible for
transporting chemically-diverse substrates into the cell (Ponte Sucre 2007).

ABC

transporters are anchored to the membrane through which they traverse by transmembrane
domains (Ponte Sucre 2007). These domains also form a pore that is responsible for
allowing the passage of transported solutes (Ponte Sucre 2007). As an ATPase, ABC
transporters contain ATP-binding domains that hydrolyze ATP to supply energy for the
transport of ions and large polypeptides or polysaccharides (Holland and Blight 1999). The
extraordinary features of ABC systems are their ability to transport a wide range of
compounds and their ability to act as an importer or exporter (Holland and Blight 1999).
Due to these abilities and their invariable linkage to a transport protein or protein domain
(Holland and Blight 1999), it is reasonable to assume ABC transporters play a potential
role in the active transport of nanoparticles for Gram-negative bacteria.
Growth Benefits from Nanoparticles
With the introduction of nanoparticles as a potential alternative treatment for antibioticresistant bacteria, it is important to determine how these nanomaterials interact with the
bacterial cell during treatment. The phenomenon of increased growth after the addition of
nanoparticles to a bacterial culture has been previously documented. In the paper by
Ghalamboran and colleagues (Ghalamboran et al 2009), they observed that the addition of
magnetite nanoparticles to a culture of Bradyrhizobium japanicum resulted in an increase
in the growth rate of the cells within the culture. The authors postulated that the increased
growth was due to a pH buffering effect imposed by the magnetite nanoparticles, which
helped to keep the pH within a favorable neutral range (Ghalamboran 2009). They also
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proposed that the nanoparticles were binding and inactivating oxygen scavengers within
the media, which increased the oxygen availability during the growth phase (Ghalamboran
2009). Other papers by Merceda et al 2006 and Flores et al 2004 suggest the increase in
growth is due to their large specific surface area and capacity to release electrons. Liu et
al 2013 postulate that the electrons released by the nanoparticles augment the enzymatic
functioning of bacterial outer membrane proteins and may accelerate electron transport
chain function, thereby facilitating cell metabolism. Another plausible theory is key
nutrients in the culture medium are non-specifically binding to the nanoparticles, causing
the cells to take up more nutrients and allowing the augmentation of their growth rate.
Several papers have shown the surface of various nanomaterials become covered by
different proteins upon entry into biological media, leading to the production of a protein
“corona” (Lundqvist et al 2008; Rahman et al 2013; Tenzer et al 2013; Lynch and Dawson
2008; Sahneh et al 2013). The protein corona develops as proteins in the biological
medium adsorb onto the surface of the nanoparticle and form an outside coating with
specific physicochemical properties, which strongly affects how the nanoparticle interacts
with cells in the medium (del Pino et al 2014; Treuel 2014). The corona consists of two
layers: a primary, high affinity protein layer (hard corona) and a secondary, low affinity
protein layer (soft corona) (Milani et al 2012). The hard corona proteins are tightly bound
and interact directly with the nanomaterial surface, while the soft corona proteins are
loosely bound and absorb to the outside of the hard corona (Rahman et al 2013). In the
paper by Saptarshi et al 2013, the authors state the protein corona, physicochemical
properties of the nanoparticle, and the properties of interacting cells all have an influence
on the uptake of nanoparticles in media (Walczyk et al 2010; Monopoli et al 2012). It is
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important to document these types of positive interactions between the nanoparticles and
bacterial cells when developing new methodologies for treatment to ensure the
nanomaterials being used do not increase the fitness of the bacteria in a way that interferes
with the ability of the nanoparticles to properly treat the infection.
Purpose of Study
In this study, the ability of ABC transporters was investigated as an energydependent mechanism to allow the entry of 20 nm fluorescent, carboxylate polystyrene
nanoparticles into the cytoplasm of planktonic Vibrio gazogenes cells. Although Vibrio
gazogenes is non-pathogenic to humans, it is a Gram-negative bacteria, and the information
gained from this study can be applied in principle to other pathogenic species. The
reasoning behind this is many resistance mechanisms in Gram-negative species, whether
non-pathogenic or pathogenic, are highly conserved; therefore, it is plausible nanoparticle
transport occurs in similar ways among different species. The hypothesis proposed is that:

Ho; Transport of 20 nm fluorescent, carboxylate polystyrene nanoparticles into Gramnegative bacterial cells is an active process, which requires the assistance of ABC
transporters.

If ABC transporters play an important role in nanoparticle transport, they can be used to
develop ground-breaking, receptor-targeting therapies that take advantage of this pathway
to treat multi-drug resistant bacteria.
In addition to determining the role of ABC transporters in nanoparticle transport, it
will also be determined if the 20 nm, fluorescent carboxylate nanoparticles have a
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positive effect on the growth of Vibrio gazogenes. This is important because it will add
more information to the discourse of the many ways in which nanoparticles interact with
bacterial cells. It is well known that some nanoparticles, like silver and gold, have
inhibitory effects on bacterial growth, but few studies have addressed the beneficial
effects nanoparticles may have on the growth capabilities of Gram-negative species. It is
crucial to understand not only the mechanisms of nanoparticle transport but also if their
transport leads to interactions which have the potential to increase the fitness of the cells.
All of this information must be taken into consideration when designing nanomedicinal
therapies for the successful treatment of antibiotic-resistant Gram-negative bacteria.
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CHAPTER 2
MATERIALS AND METHODS

Organism
The organism observed in the following experiments was a marine species of
bacteria known as Vibrio gazogenes. Colonies of V. gazogenes were isolated and purified
from estuarine water samples that were collected from a location in Georgetown, South
Carolina.

V. gazogenes is a motile, rod-shaped, Gram-negative, marine bacterium

recognizable by its small, dry, red to reddish-orange colonies when isolated on culture
plates (Harwood 1978) (Farmer 1988). The red color stems from the production of a
pigment (prodigiosin) during the growth cycle. V. gazogenes is also oxidase-negative and
does not reduce nitrate to nitrite, making it unique amongst Vibrio species (Farmer 1988).
To ensure the purification of V. gazogenes from the estuarine water samples was
successful, 16S ribosomal RNA gene sequencing was performed on the isolated bacteria
to confirm the identity. The results showed a 98.7% sequence similarity to the reference
strain of V. gazogenes listed in GenBank (accession number D11253).
Nanoparticles
The nanoparticles used to assay nanoparticle transport were 20 nm carboxylatemodified, fluorescent, polystyrene FluoSpheres® microspheres (excitation/emission =
505/515 nm) from Molecular Probes.

Carboxylate-modified FluoSpheres® have

carboxylic acid groups attached to the surface, resulting in highly negatively charged and
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relatively hydrophilic microspheres (Molecular Probes 2004). The nanoparticles were
stored as a stock suspension in 2 mM sodium azide (2% solids). Prior to sampling,
sonication was performed to disperse any aggregated nanoparticles in the storage solution.
Nanoparticle Uptake Assay
A working culture was prepared by pipetting 20 µL of a stock culture of V. gazogenes
stored at -80°C in 50% glycerol into a sterile culture tube containing 2 mL of Difco™
Marine Broth (MB). Difco™ MB has a high salt content, simulating sea water, and this
makes it an ideal growth medium for marine organisms (BD Diagnostics 2009). The
working culture was placed overnight in an incubator-shaker set at 28°C and 180 rpm.
After growing overnight, the working culture was used to make an inoculum with an OD600
of 0.082 in a sterile tube containing 1 mL of Difco™ MB. The OD600 readings were
obtained by a Shimadzu UV-2401 PC UV-VIS Recording Spectrophotometer.
Treatment samples were prepared by pipetting 50 µL of the inoculum, 49 µL of
Difco™ MB, and 1 µL of a diluted nanoparticle suspension (1 µL of the stock suspension
in 20 µL of Difco™ MB) into four wells on a sterile 96-well, black, flat bottom
polystyrene microplate. Control samples were prepared by adding 50 µL of the inoculum
and 50 µL of Difco™ MB into four additional wells on the 96-well microplate. The final
volume for the treatment wells and the sample wells (8 wells total) was 100 µL per well.
The 96-well microplate was covered with an ethanol-sterilized VWR Advanced Adhesive
Film for Microplates and placed into a Perkin Elmer 2030 Multilabel Fluorescence Plate
Reader. The reader was set at 28°C and fluorescence measurements were taken every 30
min at 490 nm for 13 hours.
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Metabolic Inhibition Assay of ABC Transporters
An overnight culture of V. gazogenes grown in Difco™ MB was used to prepare an
inoculum diluted to an OD600 of 0.080 in a sterile culture tube containing 4 mL of Difco™
MB. Potassium chloride (KCl), glucose and sucrose were used as inhibitors of the ABC
transporters in this experiment. The concentrations of each inhibitor tested were 200 mM
and 400 mM. The treatment group containing 200 mM of the KCl inhibitor was prepared
by first pipetting 50 µL of the inoculum into four wells of a sterile 96-well, black, flat
bottom polystyrene microplate. Next, 24 µL of sterile Difco™ MB and 25 µL of an 800
mM stock solution of the inhibitor prepared in Difco™ MB were added to the wells. Then,
in a sterile Eppendorf tube, 2 µL of the stock suspension of carboxylate-modified,
fluorescent, polystyrene FluoSpheres® were pipetted into 40 µL of sterile Difco™ MB and
vortexed for 10 secs.

Lastly, 1 µL of the diluted FluoSpheres® suspension in the

Eppendorf tube was pipetted into the treatment wells. The same procedure was repeated
for the 200 mM glucose and sucrose treatment groups. Each treatment well had a final
volume of 100 µL. The 400 mM concentration of the inhibitors were prepared in similar
fashion by pipetting 50 µL of the inoculum, 49 µL of the inhibitor, and 1 µL of the diluted
FluoSpheres® suspension into four treatment wells on the microplate. A final treatment
group containing 50 µL of the inoculum, 49 µL of Difco™ MB, and 1 µL of the diluted
FluoSpheres® suspension were prepared on the plate. This treatment group served as a
positive control for the experiment to show the uptake of nanoparticles in the absence of
any inhibitors. The control groups for the 200 mM concentration of the inhibitors were
prepared by adding 50 µL of inoculum, 25 µL of sterile Difco™ MB, and 25 µL of the 800
mM stock solution of the inhibitor to four wells. The 400 mM concentration control groups
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were prepared by pipetting 50 µL of the inoculum, 49 µL of the inhibitor, and 1 µL of
Difco™ MB into four wells. The 200 mM and 400 mM concentration control groups were
used to determine if any of the inhibitors had a significant effect on the fluorescence
reading of the wells in the absence of nanoparticles. The last control group prepared on
the microplate contained 50 µL of the inoculum and 50 µL of the Difco™ MB pipetted
into four wells and served as a negative control for the experiment. The 96-well microplate
was covered with VWR Advanced Adhesive Film for Microplates and placed into a Perkin
Elmer 2030 Multilabel Fluorescence Plate Reader. The reader was set at 28°C and
fluorescence measurements were taken every 30 minutes at 490 nm for 13 hours.
Growth Curve
An overnight culture of V. gazogenes grown in Difco™ MB was used to prepare an
inoculum diluted to an OD600 of 0.100 in a sterile Eppendorf tube containing 1 mL of
Difco™ MB. To prepare the control group, one hundred microliters of the inoculum was
pipetted into three culture flasks containing 99.9 mL of sterile Difco™ MB, and the
inoculum was distributed throughout the broth by manually shaking the flasks. For the
treatment group, one hundred microliters of the inoculum was pipetted into three culture
flasks containing 99.8 mL of sterile Difco™ MB. Then, one hundred microliters of the
stock suspension of carboxylate-modified, fluorescent, polystyrene FluoSpheres® were
pipetted into the same three culture flasks, and the flasks were manually shaken to
distribute the inoculum and nanoparticles.
The control and treatment flasks were placed in an incubator-shaker set at 28°C and
180 rpm. One milliliter of the culture medium was taken from each flask at 0 h, 2 h, 4 h,
6 h, 8 h, 10 h, 12 h, and 24 h and analyzed using a Shimadzu UV-2401 PC UV-VIS
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Recording Spectrophotometer to determine the optical density of the cultures at 600 nm.
Appropriate controls were used to blank the spectrophotometer prior to each reading.
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CHAPTER 3
RESULTS AND DISCUSSION

Nanoparticle Uptake Assay
Fluorescence intensity was measured at 490 nm (emiss.) for each of the four control
wells and the four treatment wells every 30 minutes over the course of 13 hours. The
measurements obtained for the control wells and treatment wells at each time point were
averaged, adjusted to account for background fluorescence from media components, and

Mean Fluorescence Intensity at 490 nm

plotted on a graph (Figure 3.1).

Nanoparticle Uptake in Vibrio gazogenes
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Figure 3.1. Mean Fluorescence Intensity of Nanoparticles after Addition to Culture of
Vibrio gazogenes over 13 h. A decrease in fluorescence intensity correlates with
uptake by cells. Values represent means ± std. dev.; (n=3).
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The average fluorescence intensity of the control wells remained relatively low until the
6 h time point where an increase of 38.46% in fluorescence was observed. Although minor
fluctuations in the average fluorescence intensity of the control wells were observed over
time, there was an overall increase of 75.82% in the fluorescence from 0 h to 13 h. The
increase in the average fluorescence intensity from the 6 h time point forward was
attributed to the production of prodigiosin by V. gazogenes. Prodigiosin is a red, waterinsoluble pigment with no defined physiological function that is produced as a secondary
metabolite during the growth cycle of V. gazogenes, with maximal pigment levels being
reached by 10 h (Allen, Reichelt, and Gray 1983). Although its exact purpose is unknown,
prodigiosin

possesses

antibacterial,

antifungal,

antiprotozoal,

anticancer,

and

immunosuppressive properties which help to increase the fitness of V. gazogenes in
competitive environments (Saha, Purkayastha, Saha 2012; Casullo de Araújo, Fukushima,
Takaki 2010). The absorption maximum of prodigiosin is pH-dependent, so two different
absorbance maximums have been noted in experiments where prodigiosin is extracted
under acidified and neutral conditions (Andreyeva and Orgorodnikova 2015). Under
neutral conditions, like the ones seen in this experiment, the absorbance maximum of
prodigiosin was between 460 and 470 nm, which was close to the absorbance of 490 nm
being measured in this experiment. Since there were no other detectable fluorescent
components in the media or added to the control wells that would account for the increase
in the average fluorescence intensity over time, it was fairly certain that the
spectrophotometer was measuring absorbance by the prodigiosin being secreted into the
media by V. gazogenes. This conclusion was also supported by the visible change in color
of the Difco™ MB from yellowish-brown to a reddish color and the leveling off of the
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average fluorescence intensity by 10 h, showing the maximal pigment level had been
reached.
The addition of nanoparticles to the treatment wells produced a high average
fluorescence intensity at T=0 h. To ensure the fluorescence signal being measured was
attributed to the nanoparticles only, the average fluorescence intensity was adjusted by
subtracting the fluorescence generated by the media, bacterial cell, and prodigiosin from
the measurements obtained at each time point. Within 30 minutes, there was a decrease of
40.82% in the average fluorescence intensity, suggesting the nanoparticles were binding
and being transported into the interior of the cell, thereby quenching their fluorescent
signal. There was a continual decrease in the average fluorescence intensity until the 5 h
mark. After 5 h, the intensity increased and then began to decrease again at the 7 h mark.
Although this pattern of decreasing and increasing continued throughout the 13 h period,
there was an overall decrease in the average fluorescence intensity of 71.18% from 0 h to
13 h. The flux of nanoparticles in the media, which was responsible for the increase and
decrease in the average fluorescence intensity over time, was probably due to the
nanoparticles being imported into the cell and then being pumped back out through an
exportation mechanism. It was plausible that components in the media were binding to the
exterior of the nanoparticles, creating a nutrient-rich protein outer shell that attracted the
bacterial cell to import the nanoparticle.

Metabolic Inhibition Assay
Metabolic inhibitors block specific chemical reactions by binding (reversibly or
irreversibly) to a target molecule, preventing the intended reaction from occurring (Winzler
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1949). In a paper by Fox et al 2006, they observed the inhibition of ABC transporters in a
wide range of Gram-negative organisms after the addition of different solutes that caused
the bacteria to experience hyperosmotic shock (osmotic upshift). Hyperosmotic shock
occurs when extracellular fluid osmolality is greater than intracellular fluid osmolality,
which creates an imbalance in cellular homeostasis and exerts osmotic pressure and stress
on the cell (Brocker et al 2012). Fox and colleagues (2006) also noted this type of
inhibition was specific to ABC transport systems and osmotic upshift had no observed
effect on non-ABC transport systems. In order to determine if the ABC transport systems
in V. gazogenes were responsible for transporting the nanoparticles into the cell, an
experiment was performed to inhibit these systems using osmotic upshift.
In this experiment, two concentrations (200 mM and 400 mM) of KCl, glucose (Glu),
and sucrose (Suc) were added to the media of V. gazogenes growing in the presence of
nanoparticles to determine if there was a significant increase in the average fluorescence
intensity of the media after the addition of the inhibitors. If the metabolic inhibitors were
able to effectively inhibit nanoparticle transport through osmotic upshift, there would be
large increases in the mean percent fluorescence intensities for the treatment samples
because blocking transport would increase the mean number of nanoparticles present,
thereby increasing the fluorescence of the media. At 0 h, there was a 10.56% increase in
the mean fluorescence intensity of the samples treated with 200 mM KCl, a 2.49%
increase for the 200 mM Glu samples, and a 19.22% increase for the Suc samples when
compared to the control samples containing no inhibitors (Figure 3.2). For the 400 mM
samples at 0 h, there was an 18.23% increase in the average fluorescence intensity for the
KCl samples, a 4.98% increase for the Glu samples, and a 4.28% increase for the Suc
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samples. The 400 mM Suc samples were the only ones that actually showed a decrease
in the average fluorescence intensity with an increase in the concentration of the inhibitor
at 0 h.

Mean Fluorescence Intensity of Nanoparticles
at 0 h
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1197
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1400

1600

No Inhibition

Figure 3.2. Mean Fluorescence Intensities of Nanoparticles after the Addition of
Metabolic Inhibitors at 0 h. Values represent mean ± std dev; (n=3).

The small increases in the percentage of average fluorescence intensity for the 200 mM
and 400 mM KCl, Glu, and Suc samples at 0 h indicate there was not a significant
difference in the mean fluorescence intensity for the control and treatment samples. To
ensure the inhibitors did not have a delayed effect on nanoparticle transport, the control
and treatment samples were measured again at 0.5 h. Figure 3.3 shows a 44% or greater
decrease in the average fluorescence intensity of each inhibitor at the 200 mM and 400 mM
concentrations when compared to the average fluorescence intensity of the inhibitors at 0
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h, which suggested the nanoparticles were being transported into the interior of V,
gazogenes without difficulty in spite of the extended exposure to the metabolic inhibitors.

Mean Fluorescence Intensity of Nanoparticles at
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Figure 3.3. Mean Fluorescence Intensities of Nanoparticles after the Addition of
Metabolic Inhibitors at 0.5 h. Values represent means ± one std dev.; (n=3).
The results of this experiment suggested the ABC transporters in V. gazogenes either
have minimal involvement in the transport of the nanoparticles into the cells or there was
another transport mechanism capable of being exploited by the nanoparticles if the ABC
transporters were not functioning properly.
Growth Curve
A bacterial growth curve is a visual representation of a bacterial species’ generation
time under optimal culture conditions. Growth curves outline the four stages of bacterial
growth: lag phase, log phase, stationary phase, and cell death (Al-Qadiri et al 2008).
During lag phase, bacteria are adjusting to the culture conditions after their inoculation into
the culture medium (Vogel et al 2014). They begin to increase in size, activate their
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metabolism, and synthesize proteins and nucleic acids in preparation for cell division
(Vogel et al 2014). Since the bacteria have not yet replicated, the lag phase is marked by
the lack of a substantial increase in cell concentration (Baranyi and Pin 1999). Following
lag phase, the cells enter into log phase, and this is the period of maximal cellular growth.
The bacteria are growing and dividing at an exponential rate, and all of the resources in the
culture medium are being exploited to support their high rate of cell division (Hall et al
2014). The cells enter into stationary phase when they have exhausted the majority of their
resources and are no longer able to sustain their rate of replication (Akerlund et al 1995).
The culture medium becomes unfavorable due to an accumulation of metabolic waste
products and a lack of nutrients, and this leads to a stabilization of the growth rate (Hall et
al 2014). Death phase marks the stage where the rate of cell death is greater than the rate
of cell replication due to the depletion of resources and increased toxicity of the culture
medium (Al-Qadiri et al 2008).
In this experiment, a growth curve was produced to identify the phases of growth for V.
gazogenes in Difco™ MB and to determine if there were any differences in the average
OD600 between the control and experimental samples after the addition of carboxylate
nanoparticles to the culture medium over a twenty-four hour period. The OD600 is a
measure of the amount of visible light that is absorbed as it passes through a bacterial
suspension at a set wavelength (i.e. 600 nm), and this provides information about the
concentration of cells within the suspension (Matlock 2011). Greater light absorbance is
indicative of a higher cell concentration. The only growth phases that could clearly be
distinguished in the control and experimental samples during the twenty-four hour period
were the lag phase and early to mid-log phase, which seemed to occur at the same time
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points within both sample sets (Figure 3.4). In order to determine the stationary and death
phases, the experiment would be required to run longer (~48 h) to give the cells more time
to stabilize their growth and deplete the resources within the culture medium.
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Figure 3.4. Comparison of the Growth Phases and Mean OD600 of Vibrio gazogenes in
the presence and absence of 20 nm (dia.) carboxylate polystyrene nanoparticles.
After the addition of the nanoparticles, there was a 16.34% increase in the average
OD600 of V. gazogenes at 8 h and a 23.94% increase at 10 h. At 12 h, the average OD600
was increased by 18.24%, and at the 24 h mark, the average OD600 was only 1% higher
than the samples without nanoparticles. This was interesting because it suggested the
carboxylate nanoparticles did not provide any major growth benefits for the cells unlike
observations made in other studies using nanoparticles. To find a possible explanation for
the absence of significant growth benefits for V. gazogenes, pH measurements of the
Difco™ MB were taken over a twenty-four hour time period to determine if the carboxylate
nanoparticles were capable of buffering the media (Table 3.1).
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Table 3.1. pH Measurements of Vibrio gazogenes Culture Medium over 24 h
Growth Time (h)
Treatment
0

2

4

6

8

10

12

16

24

Vibrio gazogenes

7.00

7.06

7.04

7.05

7.32

7.45

7.46

7.75

7.73

Vibrio gazogenes
+ nanoparticles

7.00

7.00

7.04

7.03

7.42

7.46

7.56

7.57

7.61

The results in Table 3.1 show the average pH of the control and treatment groups
increased over time, and there were very slight differences between the two groups at each
time point, which suggested the carboxylate polystyrene nanoparticles did not have the
same pH buffering effect on V. gazogenes as the magnetite nanoparticles were shown to
have on Bradyrhizobium japanicum (Ghalamboran et al 2009). It is also possible that even
if a pH buffering effect were present, it would not have a significant effect, either positively
or negatively, on the growth rate because many of the Vibrio species are very tolerant to
high pH values (Nishibuchi et al 1983; Harris et al 1996). V. gazogenes, specifically, has
an optimal growth pH of 7.5 to 8.5 (Zhan et al 1997), and Vibrio species grow to the same
maximal levels in the pH range of 6.0 to 9.0 (Nishibuchi et al 1983). The alternate theory
of a nutrient-rich protein corona on the surface of the nanoparticles causing increased
nutrients to be taken into the cell and accelerating their growth did not seem to occur in
this experiment as well. Based on the results from this experiment, the 20 nm carboxylate
polystyrene nanoparticles did not have a major effect on the growth of V. gazogenes after
their introduction into the culture medium.
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CHAPTER 4
CONCLUSION
V. gazogenes was capable of taking up 20 nm carboxylate-modified, fluorescent,
polystyrene FluoSpheres® microspheres from the culture medium under normal culture
conditions. While it was almost certain the process of uptake occurs through an active
transport system, it was unclear which system is responsible. The results of the inhibition
assay showed the ABC transporters of V. gazogenes did not play a major role in the uptake
of nanoparticles, contrary to the hypothesis initially proposed. More research is necessary
to begin elucidating the pathways involved in nanoparticle transport in this species.
The nanoparticles in this experiment did not seem to provide any significant growth
benefits for V. gazogenes, which could be important when determining what type of
nanoparticles to use in nanotherapies aimed at treating antibiotic-resistant Gram-negative
bacteria. It is possible, however, that the nanoparticles may have a beneficial growth effect
on other species, so it is necessary to experiment with different species to determine if the
growth effects are unique to certain organisms.
Nanomedicine is a complex field with many unknowns that need to be examined further
before deciding whether nanoparticle treatments are a viable option for the treatment of
recalcitrant bacteria. While there is much progress being made in this field, future research
should be geared toward determining the long-term effects of the treatments on the hosts
and the specific mechanisms responsible for the observed effects of the nanoparticles on
the bacterial cell.
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